title: Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.
abstract: Rapid virologic response (RVR) and complete early virologic response (cEVR) are associated with sustained virologic response to hepatitis C virus (HCV) therapy. We retrospectively examined baseline and on-treatment factors associated with RVR (HCV RNA undetectable at week 4) and cEVR (HCV RNA undetectable at week 12, regardless of week 4 response). The analysis comprised 1550 HCV genotype-1 patients from five clinical trials, including three enriched with difficult-to-treat populations, randomized to peginterferon alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day. Overall, 15.6% achieved RVR and 54.0% achieved cEVR. Baseline factors predictive of RVR were serum HCV RNA <or= 400,000 IU/mL (OR: 7.34; P < 0.0001), alanine aminotransferase >3 x ULN (OR: 2.01; P < 0.0001), non-cirrhotic status (OR: 1.92; P = 0.0087), age <or= 40 years (OR: 1.56; P = 0.0085), white non-Latino ethnicity (OR: 1.41; P = 0.0666) and individual study (P < 0.0001). These factors plus body mass index <or= 27 kg/m(2) were predictive of cEVR. After adjusting for these factors, mean on-treatment ribavirin dose >13 mg/kg/day was predictive of RVR (OR: 1.69; P = 0.005) and cEVR (OR: 1.24; P = 0.09), whereas peginterferon alfa-2a dose reduction was not. Greater decreases in haematologic parameters were observed in patients who achieved cEVR compared with patients who did not. In conclusion, several baseline and on-treatment factors were associated with RVR and cEVR to peginterferon alfa-2a plus ribavirin in difficult-to-treat HCV genotype-1 patients, providing important prognostic information on the antiviral response in a patient cohort that is reflective of the general chronic hepatitis C population.
authors.affiliation: Fundación de Investigación de Diego, San Juan, Puerto Rico. rodztorres@coqui.net
authors.forename: M
authors.initials: M
authors.lastname: Rodriguez-Torres
authors.forename: M S
authors.initials: MS
authors.lastname: Sulkowski
authors.forename: R T
authors.initials: RT
authors.lastname: Chung
authors.forename: F M
authors.initials: FM
authors.lastname: Hamzeh
authors.forename: D M
authors.initials: DM
authors.lastname: Jensen
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015992:Body Mass Index; D005006:Ethnicity; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000410:Alanine Transaminase; C100416:peginterferon alfa-2a
references.citation: N Engl J Med. 2009 Jan 15;360(3):257-67
references.pmid: 19144941
references.citation: Gastroenterology. 2008 Aug;135(2):451-8
references.pmid: 18503773
references.citation: J Viral Hepat. 2007 Oct;14(10):721-9
references.pmid: 17875007
references.citation: J Hepatol. 2002 Oct;37(4):500-6
references.pmid: 12217604
references.citation: Hepatology. 2006 May;43(5):954-60
references.pmid: 16628671
references.citation: Liver Int. 2008 Jan;28(1):61-71
references.pmid: 17971091
references.citation: Hepatology. 2008 Oct;48(4):1033-43
references.pmid: 18697207
references.citation: Hepatology. 2008 Jan;47(1):43-50
references.pmid: 18069698
references.citation: Ann Intern Med. 2004 Mar 2;140(5):346-55
references.pmid: 14996676
references.citation: J Gastrointestin Liver Dis. 2007 Mar;16(1):23-9
references.pmid: 17410285
references.citation: Clin Gastroenterol Hepatol. 2008 Feb;6(2):234-41
references.pmid: 18237873
references.citation: J Hepatol. 2005 Sep;43(3):425-33
references.pmid: 15990196
references.citation: Clin Gastroenterol Hepatol. 2007 Jan;5(1):124-9
references.pmid: 17196435
references.citation: J Hepatol. 1999;31 Suppl 1:237-43
references.pmid: 10622595
references.citation: Gastroenterology. 2006 Aug;131(2):478-84
references.pmid: 16890602
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: J Viral Hepat. 2002 Sep;9(5):334-9
references.pmid: 12225327
references.citation: J Antimicrob Chemother. 2004 Jan;53(1):15-8
references.pmid: 14645325
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Hepatology. 2004 Jun;39(6):1702-8
references.pmid: 15185312
references.citation: Hepatology. 2008 Jun;47(6):1884-93
references.pmid: 18508296
references.citation: J Clin Gastroenterol. 2005 Jan;39(1 Suppl):S3-8
references.pmid: 15597025
references.citation: Hepatology. 2003 Sep;38(3):645-52
references.pmid: 12939591